Conversely, serum-derived exosomal miR-125a-3p serves as a potential predictor of the response to anti-PD-1/PD-L1 therapy in advanced NSCLC patients with low PD-L1 expression [172]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.